Entero Healthcare Solutions Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
ENTERO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Entero Healthcare reported mixed FY2026 results. On a consolidated basis, revenue grew 29% to Rs. 65.91 billion from Rs. 50.96 billion, with PAT rising 36% to Rs. 1,458.4 million versus Rs. 1,074.3 million. However, standalone revenue declined 15% to Rs. 3,482 million from Rs. 4,087 million, though standalone PAT improved to Rs. 268.8 million from Rs. 191.8 million. An exceptional item of Rs. 81.78 million (consolidated) was recognized due to incremental employee benefit obligations under the New Labour Codes. The company completed multiple acquisitions during the year, including Ramson Medical, Sat K Pharma, Well Wisher Pharma, and others, contributing to consolidated growth. Standalone operating cash flow was negative at Rs. 581 million. Auditors MSKA & Associates gave an unmodified (clean) opinion.
Consolidated performance shows strong growth driven by acquisitions, but standalone revenue decline and negative operating cash flow may raise concerns about underlying business quality. The exceptional labour code charge is a one-time item.